LIS22
Peripheral T-Cell Lymphoma (PTCL)
Phase 1/2Active
Key Facts
About Xenothera
Xenothera is a clinical-stage biotech with a unique focus on engineering polyclonal antibodies. Its core technology, glyco-humanization (GH), removes non-human sugar antigens from antibodies derived from animals, aiming to create multispecific, low-immunogenicity therapies. The company has built an active pipeline targeting solid tumors, T-cell lymphomas, and infectious diseases, with its lead oncology candidate, XON7, already in clinical trials since 2023. Backed by a seasoned leadership team and strategic collaborations, Xenothera is positioning itself as an innovator in complex antibody therapeutics.
View full company profileTherapeutic Areas
Other Peripheral T-Cell Lymphoma (PTCL) Drugs
| Drug | Company | Phase |
|---|---|---|
| DARVIAS® (SP-02) | Solasia Pharma K.K. | Launched |
| Lacutamab (IPH4102) | Innate Pharma | Phase 2 |